item management s discussion and analysis of financial condition and results of operations the company has generated limited revenues from product sales and is dependent upon external financing  interest income  and research and development contracts to pursue its intended business activities 
the company has not been profitable since inception and has incurred a cumulative net loss of  through december  losses have resulted principally from costs incurred in research activities aimed at identifying and developing the company s product candidates  clinical research studies  merger and acquisition costs  the write off of purchased research and development  and general and administrative expenses 
the company expects to incur additional operating losses over the next several years as the company s research and development and clinical trials programs continue 
the company s ability to achieve profitability is dependent on its ability to develop and obtain regulatory approvals for its products  to enter into agreements for product development and commercialization with strategic corporate partners and to develop the capacity to manufacture and sell its products  and to secure additional financing 
see management s discussion and analysis of financial condition and results of operations liquidity and capital resources 
results of operations years ended december  and total revenues decreased by  from revenues in related to fees the company received as a result of sublicensing certain technologies which were not being actively developed by the company 
total operating expenses increased by  or  from  in to  in due to increased research and development spending partially offset by lower general  administrative and other expenses 
research and development expenses increased by  or  primarily due to significant spending on clinical trails in during the past year  the company initiated and completed phase iii clinical trials of lotemax tm for the treatment of uveitis and post cataract surgery as well as phase iii clinical trials of le a for the treatment of seasonal ocular allergies 
in october of  the company commenced a phase ii study of hu for severe head injury 
in february  the company submitted an nda for le a and in march  the company amended and supplemented the previously filed nda for lotemax with the results of the clinical trials 
the increased clinical trial expenses were partially offset by cost saving measures taken by the company in early that focused research and development activities on products which were closest to commercialization 
bausch lomb net reimbursements for clinical trials totaled million during  thereby reducing research and development expenses by this amount 
patent expense decreased by  or  in the company was able to reduce patent maintenance costs by returning to an original patent holder several patents covering technologies which are no longer being pursued 
further  the company s in house patent counsel now executes work previously undertaken by external patent attorneys 
general and administrative costs decreased by  or  in this reduction resulted primarily from the relocation of corporate headquarters from new york to the company s existing facility in alachua  florida 
depreciation and amortization expenses decreased by  or  in due to the absence in of depreciation of new york facilities following the closing  a write off of certain leasehold improvements  as well as reduced depreciation relating to the florida operation 
net interest income increased by  in  reflecting the higher level of investable funds in in addition  the company had higher interest expense in relating to interest on the convertible debentures issued by the company in february  and converted into common stock by july  and a note that was paid in full 
years ended december  and total revenues increased by  from  in to  in this increase resulted from a fee the company received as a result of sublicensing certain technologies which were not being actively developed by the company 
revenues in related to sales of fine chemicals 
the company phased out the selling of speciality chemicals and no such revenues were received in total operating expenses decreased by  or  from  in to  in primarily due to decreases in research and development expenses  patent expenses and general and administrative expenses 
research and development expenses decreased by  or  primarily due to certain clinical trials of the company s lead product lotemax tm being substantially completed in  the company submitted a new drug application nda for this product with the federal drug administration fda in march late in  the company began clinical trial testing on one of its lotemax line extension products 
patent expenses decreased by  or  in this decrease reflects a return to more normalized levels of patent expenses as was impacted by costs of defending patent challenges related to technologies licensed by the company 
in addition patent expenses in were impacted by costs associated with improving the company s patent coverage for its lead product lotemax tm and its dexanabinol and tamoxifen methiodide compounds 
general and administrative expenses decreased by  or  in primarily reflecting the impact of the cost savings which resulted from the company s decisions in late and early to eliminate staff and relocate its corporate headquarters from new york to alachua  florida 
in the company recognized costs of approximately  related to this restructuring primarily for severance and relocation expenses 
net interest income in of  represented an increase of compared to  and was comprised of interest income of  offset by interest expense of  interest income in increased by  or  compared to and resulted from the company s higher level of investible funds in interest expense in increased by  or compared to and resulted from interest expense on the convertible debentures issued by the company in february and converted into common stock by july the net loss for of  reflected a decrease of  or  from the net loss of  for the decrease in operating expenses described above accounted for substantially all of this decrease 
liquidity and capital resources the company currently has no sources of recurring revenues and has incurred operating losses since its inception and has financed its operations with public and private offerings of securities  advances and other funding pursuant to a marketing agreement with bausch lomb  research contracts  license fees  royalties and sales  and interest income 
the company had working capital of million  including cash and cash equivalents of million  as of december  in march  the company received an additional million cash advance from bausch lomb following the nda submission for le a   of which was subsequently advanced to the license holder 
on march  the company completed a million private placement of convertible preferred stock and warrants 
management believes that existing cash and cash equivalents combined with additional cash inflows from investment income and grants will be sufficient to support operations into the first quarter of management believes that additional funding will be required to fund operations until  if ever  profitable operations can be achieved 
therefore  the company is continuing to actively pursue various funding options  including additional equity offerings  strategic corporate alliances  business combinations and the establishment of product related research and development limited partnerships  to obtain the additional financing that would be required to continue the the development of its products and bring them to commercial markets 
during  the company raised additional equity of million through the issuance of common stock  convertible preferred stock and warrants 
all net proceeds were available to fund the company s operations 
in addition  during  the company signed an international marketing agreement with bausch lomb to market  upon regulatory approval  the company s three leading ophthalmic products including lotemax tm in europe  canada and other selected countries 
under this agreement  bausch lomb will provide the company with million in cash advances upon receipt of regulatory approvals in these markets 
pursuant to the us marketing agreement with bausch lomb  as of march   the company has received million million as of december  in advances against future sales of the active drug substance needed to manufacture the drug 
bausch lomb will be entitled to credits against such future purchases of the drug substance until the advances have been recouped 
the company may be obligated to repay such advances if it is unable to supply bausch lomb with certain specified quantities of the active drug substance 

